Advertisement

Topics

Acceleron Pharma and Celgene Corporation Company Profile

12:24 EST 14th November 2018 | BioPortfolio

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.


News Articles [1141 Associated News Articles listed on BioPortfolio]

Celgene, Acceleron to seek FDA nod for myelodysplastic syndrome drug

Celgene and Acceleron Pharma intend to file with the US and Europe next year regulatory applications for ACE-536, or luspater -More- 

Celgene, Acceleron to file MDS therapy in the EU, US

Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.

Luspatercept: Acceleron/Celgene team-up yields positive results

On June 28, Celgene and Acceleron announced that their lead product candidate luspatercept (ACE-536) met its primary and secondary endpoints...Read More... The post Luspatercept: Acceleron/Celgene tea...

Acceleron Pharma Appoints Robert Zeldin Chief Medical Officer

Robert Zeldin has been appointed chief medical officer of Cambridge, MA, drug developer Acceleron Pharma (NASDAQ: XLRN). Zeldin joins Acceleron from Belgium-based Ablynx, where he was chief medical of...

Celgene and Acceleron’s Luspatercept Hits Primary Endpoints in Beta-Thalassemia Trial

Celgene Corporation and Acceleron Pharma indicated their Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.

Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia

SUMMIT, N.J. & CAMBRIDGE, Mass.--July 9, 2018 (BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, do...

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study

Celgene (NASDAQ: CELG) and Acceleron Pharma (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly st...

Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder

A drug from Celgene and Acceleron Pharma has met the main goals of a late-stage test as a treatment for a rare blood disorder, the second set of positive results that the partners have released for th...

PubMed Articles [26 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Artificial Intelligence and the Future of the Drug Safety Professional.

The healthcare industry, and specifically the pharmacovigilance industry, recognizes the need to support the increasing amount of data received from individual case safety reports (ICSRs). To cope wit...

Clinical trials go virtual, big pharma dives in.

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

Clinical Trials [94 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a p...

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

Companies [969 Associated Companies listed on BioPortfolio]

Acceleron Pharma, Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth a...

Acceleron Pharma & Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth a...

Acceleron Pharma and Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The...

Acceleron Pharma, Inc.

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood c...

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

More Information about "Acceleron Pharma and Celgene Corporation" on BioPortfolio

We have published hundreds of Acceleron Pharma and Celgene Corporation news stories on BioPortfolio along with dozens of Acceleron Pharma and Celgene Corporation Clinical Trials and PubMed Articles about Acceleron Pharma and Celgene Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acceleron Pharma and Celgene Corporation Companies in our database. You can also find out about relevant Acceleron Pharma and Celgene Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record